No products in the cart.
Pre-made Labetuzumab benchmark antibody ( Whole mAb ADC, anti-CEACAM5/CD66e therapeutic antibody, Anti-CEA Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-288
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Labetuzumab biosimilar, Whole mAb ADC, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5.
| Products Name (INN Index) | Pre-Made Labetuzumab biosimilar, Whole mAb ADC, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody |
|---|---|
| INN Name | Labetuzumab |
| Target | CEACAM5 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Immunomedics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Colorectal cancer,Ovarian cancer,Breast cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CEACAM5 |
| Package |
Previous slide
Next slide
